Type 2 diabetes mellitus (T2DM) is the most common cause of chronic kidney disease (CKD) globally. Multiple risk factor management is essential in such patients to delay the disease progression [1] ; however, the management of blood glucose presents a particular challenge, with limited treatment options available beyond exogenous insulin therapy [2] [3] [4] [5] .
Patients with T2DM and CKD are at particular risk of hypoglycemia and its adverse consequences. Dipeptidyl peptidase-4 (DPP-4) inhibitors provide a simple, oral, glucosesensitive treatment option that does not increase the risk of hypoglycemia and does not confound the comorbidities that afflict many of the other drugs used to treat T2DM [2] . In addition, DPP-4 inhibitors have been shown to be associated with no further decline in estimated glomerular filtration rate (eGFR) when treating patients with CKD [2] . In recent years, several DPP-4 inhibitors have become available and have been extensively evaluated in patients with T2DM and varying degrees of renal impairment (RI). These studies have demonstrated good efficacy and tolerability of the DPP-4 inhibitor class in these patients, and have subsequently led to regulatory approval for the use in patients with T2DM and reduced eGFR due to CKD. Indeed, only exogenous insulin and DPP-4 inhibitors are indicated and now utilized widely across all thresholds of renal function, including end-stage renal disease (ESRD; Fig. 1 ) [2, [6] [7] [8] [9] [10] [11] .
Unlike linagliptin, with other DPP-4 inhibitors the drug exposure increases with decreasing renal function ( Fig. 1 ). Thus, doses or dose frequencies are recommended to be reduced according to standard renal thresholds [2, [6] [7] [8] [9] [10] [11] [12] . However, changes in renal function should be seen as a continuum; the thresholds from mild to moderate RI and from moderate to severe RI (see Fig. 1 
for definitions) are
Electronic supplementary material The online version of this article (doi:10.1007/s13300-015-0104-4) contains supplementary material, which is available to authorized users. convenient delineations based on definitions of renal function that are in common usage [13] , rather than dictated by clear discontinuities in exposure. For instance, if a patient is seen at one visit with an eGFR of about 55 mL/min/1.73 m 2 and a few months later at the next visit with an eGFR at approximately 45 mL/min/1.73 m 2 , the physician needs to be aware of this significant decline in renal function, but its impact on drug exposure will not be anywhere near the doubling of exposure implied by the following dosage strength or frequency recommendations. The labeling for sitagliptin, saxagliptin, and alogliptin recommends dosage strength adjustments depending on the level of renal function, with presumably no loss of efficacy [2, [6] [7] [8] . Vildagliptin 50 mg efficacy is maintained when the frequency of dosing is reduced from twice daily in patients with normal renal function to once daily in patients with moderate or severe RI, in accordance with its label [2, 10] . The dose adjustments thus require regular monitoring of renal function, which is also good clinical practice because in these patients it is important to closely monitor renal disease progression. Other than the specifications for modifications in dose or dose frequency, there appears to be no difference between each DPP-4 inhibitor with respect to their safety and tolerability in patients with T2DM and CKD [11] .
In a recent review article on linagliptin [14] , Thus, any concern that accumulation of vildagliptin (or its renally excreted metabolites) results in an increase in renal or other toxicities is not supported by data. To our knowledge, this is also true for the entire DPP-4 inhibitor class.
In conclusion, DPP-4 inhibitors represent an appealing treatment option for the management of blood glucose control in people with T2DM and CKD. There is a wealth of literature, clinical experience, and regulatory review indicating that there is no evidence of any safety differences between the various individual agents within the class. It is important to remember that there is a continuum of renal function in patients with diabetes, with declining renal function associated with increasing age. As renal kidney dysfunction progresses, there is an increased risk of adverse clinical outcomes including acute kidney injury, falls, frailty, and mortality. Furthermore, in association with progressive RI, some coexisting conditions become more common and increase in severity, while the risk of adverse events associated with commonly used drugs such as metformin increases with declining renal function, in addition progression to ESRD can also occur in a small but significant group of for editorial support which was funded by Novartis. No further funding was received for publication of this manuscript.
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